CN101283279A - 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法 - Google Patents

以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法 Download PDF

Info

Publication number
CN101283279A
CN101283279A CNA200680035270XA CN200680035270A CN101283279A CN 101283279 A CN101283279 A CN 101283279A CN A200680035270X A CNA200680035270X A CN A200680035270XA CN 200680035270 A CN200680035270 A CN 200680035270A CN 101283279 A CN101283279 A CN 101283279A
Authority
CN
China
Prior art keywords
seq
cdca1
kntc2
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680035270XA
Other languages
English (en)
Chinese (zh)
Inventor
中村佑辅
醍醐弥太郎
中鹤修一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN101283279A publication Critical patent/CN101283279A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CNA200680035270XA 2005-07-29 2006-07-19 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法 Pending CN101283279A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70370405P 2005-07-29 2005-07-29
US60/703,704 2005-07-29

Publications (1)

Publication Number Publication Date
CN101283279A true CN101283279A (zh) 2008-10-08

Family

ID=37434044

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680035270XA Pending CN101283279A (zh) 2005-07-29 2006-07-19 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法

Country Status (5)

Country Link
US (2) US7943295B2 (enExample)
EP (1) EP1915622A2 (enExample)
JP (1) JP5150855B2 (enExample)
CN (1) CN101283279A (enExample)
WO (1) WO2007013480A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791295A (zh) * 2010-02-12 2012-11-21 普罗卡塔生物系统有限公司 核酸复合物
CN107074908A (zh) * 2014-08-04 2017-08-18 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184047A1 (en) * 2007-03-30 2010-07-22 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
MX2010002001A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NZ516381A (en) * 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer
EP1343886A2 (en) * 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2003218238A1 (en) * 2002-03-15 2003-09-29 Incyte Corporation Proteins associated with growth, differentiation, and death
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0306085D0 (en) * 2002-12-04 2003-04-23 Unilever Plc Improved composition for topical application
AU2003300680A1 (en) * 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20040171823A1 (en) * 2003-01-14 2004-09-02 Nadler Steven G. Polynucleotides and polypeptides associated with the NF-kappaB pathway
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8193332B2 (en) * 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
MX2010002001A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791295A (zh) * 2010-02-12 2012-11-21 普罗卡塔生物系统有限公司 核酸复合物
CN107074908A (zh) * 2014-08-04 2017-08-18 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗
CN107074908B (zh) * 2014-08-04 2021-10-15 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗

Also Published As

Publication number Publication date
US7943295B2 (en) 2011-05-17
US20090215683A1 (en) 2009-08-27
US20110263012A1 (en) 2011-10-27
WO2007013480A2 (en) 2007-02-01
JP2009505633A (ja) 2009-02-12
EP1915622A2 (en) 2008-04-30
JP5150855B2 (ja) 2013-02-27
WO2007013480A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
KR101075158B1 (ko) 비-소세포성 폐암을 진단하는 방법
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
KR20100075857A (ko) 폐암의 치료 및 진단의 표적유전자인 ｅｂｉ３，ｄｌｘ５，ｎｐｔｘ１ 및 ｃｄｋｎ
KR20090064378A (ko) 유방암 관련 유전자 및 폴리펩티드
CN101835893A (zh) 癌症相关基因cdca5、epha7、stk31和wdhd1
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
US20110014615A1 (en) METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
KR101325194B1 (ko) 대장암 관련 유전자 ｔｏｍ３４
CN101273131A (zh) 胰腺癌相关基因cst6和gabrp
CN101528768A (zh) 与乳腺癌相关的基因和多肽
KR20110067107A (ko) 종양 마커 및 암에 대한 치료적 표적으로서 ｔｂｃ１ｄ７
US8067153B2 (en) Genes and polypeptides relating to prostate cancers
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2011518541A (ja) 癌治療法および癌診断のための標的遺伝子としてのＣ２ｏｒｆ１８
US20110313018A1 (en) Cancer related gene, lgn/gpsm2
CN101278060A (zh) 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
JP2008505601A (ja) 前立腺癌に関連した遺伝子及びポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081008